Also known as: Sunitinib Base
Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor used in the treatment of renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. It exerts its effects by inhibiting PDGFR, VEGFR, KIT, FLT3, CSF-1R, and RET pathways, resulting in anti-tumor and anti-angiogenic activity. Mediocon Inc manufactures pharmaceutical-grade Sunitinib API meeting IP/BP/EP/USP specifications at its GMP-certified facility in Aurangabad, Maharashtra.
| Parameter | Specification |
|---|---|
| CAS Number | 557795-19-4 |
| Molecular Formula | C₂₂H₂₇FN₄O₂ |
| Molecular Weight | 398.47 g/mol |
| Grade | IP / BP / EP / USP |
| Category | Antineoplastic / Tyrosine Kinase Inhibitor |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |